Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1986738 | 0.86 | — | — | |
| SCHEMBL1983895 | 0.86 | — | — | |
| SCHEMBL2212358 | 0.82 | GPR119 (0.35) | GPR119 | |
| SCHEMBL2642214 | 0.79 | GPR119 (0.30) | GPR119 | |
| SCHEMBL8516141 | 0.78 | GPR119 (0.32) | GPR119 | |
| SCHEMBL25346880 | 0.76 | GPR119 (0.31) | GPR119 | |
| SCHEMBL51112 | 0.76 | GPR119 (0.34) | GPR119 | |
| SCHEMBL442550 | 0.76 | CYP3A4 (0.44) | GPR119 | |
| SCHEMBL87245 | 0.76 | POLB (0.42) | GPR119 | |
| SCHEMBL52393 | 0.76 | GPR119 (0.31) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020233512-A1 | AROMATIC AMINE AR AND BET TARGETING PROTEIN DEGRADATION CHIMERA COMPOUND AND USE | 成都海创药业有限公司 (CN) | 2020-11-26 | — | — | WO | disclosed |
| WO-2015158603-A1 | MALONONITRILE OXIME COMPOUNDS | BASF SE (DE) | 2015-10-22 | — | — | WO | disclosed |
| EP-2366704-B1 | Inhibitors of serine proteases | VERTEX PHARMA (US) | 2013-10-23 | — | — | EP | disclosed |
| US-8207146-B2 | Phenothiazine derivative having a double bond, method for the production thereof, and use thereof as a pharmaceutical | SANOFI-AVENTIS (FR) | 2012-06-26 | — | — | US | disclosed |
| US-8207146-B2 | Phenothiazine derivative having a double bond, method for the production thereof, and use thereof as a pharmaceutical | SANOFI-AVENTIS (FR) | 2012-06-26 | — | — | US | disclosed |
| US-8207146-B2 | Phenothiazine derivative having a double bond, method for the production thereof, and use thereof as a pharmaceutical | SANOFI-AVENTIS (FR) | 2012-06-26 | — | — | US | disclosed |
| US-7999115-B2 | Spiro antibiotic derivatives | ACTELION PHARMACEUTICAL LTD. (SE) | 2011-08-16 | — | — | US | disclosed |
| EP-2114937-B1 | PHENOTHIAZIN DERIVATES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS PHARMACEUTICALS | SANOFI AVENTIS (FR) | 2011-06-29 | — | — | EP | disclosed |
| EP-2203448-B1 | PHENOTHIAZINE DERIVATIVE HAVING A DOUBLE BOND, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A PHARMACEUTICAL | SANOFI AVENTIS (FR) | 2011-06-22 | — | — | EP | disclosed |
| EP-2203448-B1 | PHENOTHIAZINE DERIVATIVE HAVING A DOUBLE BOND, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A PHARMACEUTICAL | SANOFI AVENTIS (FR) | 2011-06-22 | — | — | EP | disclosed |
| WO-2008089892-A1 | PHENOTHIAZIN DERIVATES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2008-07-31 | — | — | WO | disclosed |
| WO-2008026172-A1 | SPIRO ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-06 | — | — | WO | disclosed |
| US-7259166-B2 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2007-08-21 | — | — | US | disclosed |
| EP-1501815-B1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2006-11-22 | — | — | EP | disclosed |
| US-7105671-B2 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2006-09-12 | — | — | US | disclosed |
| US-20060178429-A1 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | CORBETT WENDY L | 2006-08-10 | — | — | US | disclosed |
| EP-1501815-A1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003095438-A9 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2004-12-23 | — | — | WO | disclosed |
| US-20030225283-A1 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | CORBETT WENDY LEA (US) | 2003-12-04 | — | — | US | disclosed |
| WO-2003095438-A1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178429-A1 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | GCKR, GCK, PDXK | GPR119 10/4885 |
| US-20030225283-A1 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | GCKR, GCK, PDXK | GPR119 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.